CD4 and neoplasm: We anticipate that patients who respond to treatment with NSC-CRAd-S-pk7 will show evidence of anti-tumor immune responses, including activation and infiltration of CD4+ and CD8+ T-cells, natural killer cells, reduced Tregs and a polarization of macrophages towards an anti-tumor phenotypic state.